Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) CFO Sells 5,886 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) CFO Adam Laponis sold 5,886 shares of the firm’s stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $43.26, for a total value of $254,628.36. Following the completion of the transaction, the chief financial officer now owns 110,096 shares in the company, valued at approximately $4,762,752.96. This trade represents a 5.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Adam Laponis also recently made the following trade(s):

• On Wednesday, November 6th, Adam Laponis sold 4,160 shares of Twist Bioscience stock. The stock was sold at an average price of $44.60, for a total transaction of $185,536.00.

Twist Bioscience Stock Down 1.9 %

TWST stock traded down $0.83 during trading on Tuesday, hitting $42.75. 915,536 shares of the company’s stock traded hands, compared to its average volume of 638,913. The stock has a fifty day moving average price of $46.43 and a two-hundred day moving average price of $46.38. Twist Bioscience Co. has a 52 week low of $27.41 and a 52 week high of $60.90. The stock has a market capitalization of $2.54 billion, a price-to-earnings ratio of -11.88 and a beta of 1.85.

Analysts Set New Price Targets

A number of research firms have weighed in on TWST. TD Cowen restated a “buy” rating and issued a $58.00 price target on shares of Twist Bioscience in a report on Tuesday, November 26th. Evercore ISI boosted their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Robert W. Baird raised their target price on Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a research note on Tuesday, November 19th. Scotiabank boosted their price target on Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, November 19th. Finally, Leerink Partners raised their price objective on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $51.90.

Hedge Funds Weigh In On Twist Bioscience

A number of hedge funds and other institutional investors have recently bought and sold shares of TWST. Wilmington Savings Fund Society FSB acquired a new stake in Twist Bioscience in the 3rd quarter valued at approximately $34,000. Signaturefd LLC increased its holdings in shares of Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after purchasing an additional 306 shares during the period. DekaBank Deutsche Girozentrale bought a new stake in shares of Twist Bioscience during the second quarter valued at about $61,000. Beaird Harris Wealth Management LLC acquired a new stake in Twist Bioscience in the third quarter worth about $95,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in Twist Bioscience by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after buying an additional 381 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.